Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-08-23
2011-08-23
Stucker, Jeffrey (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S141100, C424S142100, C424S130100, C424S133100, C530S351000, C530S389100, C514S012200
Reexamination Certificate
active
08003104
ABSTRACT:
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5723299 (1998-03-01), Bell et al.
patent: 5789192 (1998-08-01), Moore et al.
patent: 5843725 (1998-12-01), Sledziewski et al.
patent: 5945511 (1999-08-01), Lok et al.
patent: 5985614 (1999-11-01), Rosen et al.
patent: 6020163 (2000-02-01), Conklin
patent: 6486301 (2002-11-01), Ebner et al.
patent: 6576743 (2003-06-01), Conklin et al.
patent: 6610286 (2003-08-01), Thompson et al.
patent: 7115714 (2006-10-01), Conklin et al.
patent: 7119175 (2006-10-01), Conklin et al.
patent: 7119191 (2006-10-01), Conklin et al.
patent: 7122352 (2006-10-01), Conklin et al.
patent: 7151166 (2006-12-01), Conklin et al.
patent: 7189394 (2007-03-01), Thompson et al.
patent: 7271246 (2007-09-01), Conklin et al.
patent: 7364732 (2008-04-01), Thompson et al.
patent: 7393684 (2008-07-01), Xu et al.
patent: 7582287 (2009-09-01), Chandrasekher et al.
patent: 7601830 (2009-10-01), Conklin et al.
patent: 2006/0287507 (2006-12-01), Conklin et al.
patent: 2006/0287514 (2006-12-01), Conklin et al.
patent: 2007/0141670 (2007-06-01), Conklin et al.
patent: 2008/0171041 (2008-07-01), Thompson et al.
patent: 2008/0247945 (2008-10-01), Xu et al.
patent: 2010/0015703 (2010-01-01), Conklin et al.
patent: 1719780 (1998-11-01), None
patent: 9903982 (1999-01-01), None
patent: 9927103 (1999-06-01), None
patent: 9946379 (1999-09-01), None
patent: WO 99/62934 (1999-12-01), None
patent: 0042189 (2000-07-01), None
patent: WO 00/39161 (2000-07-01), None
patent: WO 01/46261 (2001-06-01), None
Blumberg et al, Cell, Jan. 12, 2001, vol. 104, pp. 9-19.
Rich, B.E. et al.; “Cytokines: IL-20—a new effector in skin inflammation”; Current Biology; 11:R531-R534; 2001.
Mckinnon, M. et al.; “Strategies for the Discovery of Cytokine Receptor Antagonists”; Drug News and Perspectives; 9:389-398; 1996.
Mohler, K.M. et al.; “Immunotherapeutic Potential of Soluble Cytokine Receptors in Inflammatory Disease”; FASB J. US Fed of American Soc. for Experimental Biology; 6(4):A1123, 1992.
Davis, S. et al.; “Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning”; Cell; 87:1161-1169; 1996.
Dynan, W.S. et al.; “Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins”; Nature; 316:774-778; 1985.
Mijares, A. et al.; “From Agonist To Antagonist: Fab Fragments of an Agonist-Like Monoclonal Anti-b2-Adrenoceptor Antibody Behave as Antagonists”; Molecular Pharmacology; 58:373-379; 2000.
Choy, E.; Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis; Cytokine; 28:158-161; 2004.
Borrebaeck, C. AK et al.; “Human therapeutic antibodies”; Current Opinion in Pharmacology; 1:404-408; 2001.
U.S. Appl. No. 11/458,666, Official Communication mailed Apr. 19, 2007 (7pp).
U.S. Appl. No. 10/424,658, Official Communication mailed Mar. 28, 2006 (9pp).
Communication from European Patent Office dated Jun. 12, 2005, for corresponding European Application No. 05020542 (3pp).
Japanese Patent Application No. 2001-547170: Notice of Reasons for Rejection dated Dec. 16, 2010, 10 pages.
U.S. Appl. No. 09/199,586, filed on Nov. 25, 1998, Conklin.
Cunningham et al., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,”Science, 1989, 244, 1081-1085.
George et al., “Current Methods in Sequence Comparison and Analysis,”Macromolecular Sequencing&Synthesis, Alan R. Liss, Inc., 1988, Ch. 12, 127-149.
Harlow et al.,Antibodies A Laboratory Manual, Cold Springs Harbor Laboratory, 1988, Ch. 5, 76.
Incyte Pharmaceuticals Inc., INC819592, Mar. 5, 1996, 1 page.
Incyte Pharmaceuticals Inc., INC4304592, Jul. 9, 1998, 1 page.
Lederman et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4,”Molecular Immunol., 1991, 28, (11),1171-1181.
Li et al., “Beta-Endorphin Omission Analogs: Dissociation of immunoreactiviety from other biolgoical activities,”Proc Natl Aced Sci USA, 1980, 77(6), 3211-3214.
Mikayama, T., “Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor,”Proceedings of the National Academy of Sciences, 1993, (90), 10056-10060.
Rich, B. E., “IL-20: a new target for the treatment of inflammatory skin disease,”Expert Opin. Ther. Targets, 2003, 7(2), 165-174.
Rohovsky et al., “Growth factors and angiogenesis in wound healing,”Growth Factors Wound Healing, Eds: Ziegler T.R. et. al., Springer New York N.Y., 1997, 8-26.
Slavin, “Cytokines and tissue repair,”J. lmmunol. Immunopharmacol, 1997, 17(1),25-29.
Voet et al.,Biochemistry, John Wiley & Sons, Inc., 1990, 126-128 and 228-234.
Volk et al., “IL-10 and its homologs: important immune mediators and emerging immunotherapeutics agents,”TRENDS in Immunology, 2001, 22(8), 414-417.
Wuyts et al., “Isolation of the CXC chemokines ENA-87, GRO-alpha and GRO-gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms,”Eur. J. Biochem, 1999, 260, 421-429.
U.S. Appl. No. 10/748,484: Non-Final Office Action dated Nov. 18, 2005.
U.S. Appl. No. 10/748,484: Final Rejection dated Apr. 5, 2006.
U.S. Appl. No. 10/748,484: Notice of Allowance dated Jul. 11, 2006.
U.S. Appl. No. 10/789,251: Non-Final Office Action dated Jan. 27, 2006.
U.S. Appl. No. 10/789,251: Notice of Allowance dated Jun. 8, 2006.
Blumberg Hal
Chandrasekher Yasmin A.
Novak Julia E.
Thompson Penny
Hamud Fozia M
Stucker Jeffrey
Woodcock & Washburn LLP
ZymoGenetics Inc.
LandOfFree
Method for treating inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2760568